C4 Therapeutics (CCCC) Projected to Announce Quarterly Earnings on Thursday

C4 Therapeutics (NASDAQ:CCCC) is expected to release its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect C4 Therapeutics to post earnings of ($0.1945) per share and revenue of $8.52 million for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Wednesday, November 11, 2026 at 12:30 PM ET.

C4 Therapeutics (NASDAQ:CCCC) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.05. The business had revenue of $6.64 million during the quarter, compared to the consensus estimate of $4.00 million. C4 Therapeutics had a negative net margin of 289.44% and a negative return on equity of 45.45%. On average, analysts expect C4 Therapeutics to post ($0.81) EPS for the current fiscal year and ($0.95) EPS for the next fiscal year.

C4 Therapeutics Stock Performance

Shares of CCCC stock opened at $3.21 on Wednesday. The firm has a market capitalization of $394.93 million, a PE ratio of -3.21 and a beta of 3.16. The firm has a fifty day simple moving average of $3.29 and a two-hundred day simple moving average of $3.21. C4 Therapeutics has a 12 month low of $1.69 and a 12 month high of $5.17.

Analysts Set New Price Targets

CCCC has been the subject of a number of analyst reports. Lake Street Capital began coverage on shares of C4 Therapeutics in a report on Wednesday, October 28th. They set a “buy” rating and a $11.00 price objective for the company. Evercore downgraded shares of C4 Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday. JPMorgan Chase & Co. began coverage on shares of C4 Therapeutics in a report on Friday, October 9th. They issued an “overweight” rating and a $10.00 target price on the stock. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of C4 Therapeutics in a research report on Thursday, October 15th. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $9.33.

About C4 Therapeutics

C4 Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines that selectively eliminate disease-causing proteins. The company uses its proprietary TORPEDO platform to design targeted protein degraders, which are intended to direct specific proteins to the cell’s natural disposal system rather than simply blocking their activity.

C4 Therapeutics has concentrated its research and development efforts primarily on oncology, including programs aimed at genetically defined cancers and difficult-to-treat tumors.